Compare USAS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | LUNG |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 57.9M |
| IPO Year | 2004 | 2020 |
| Metric | USAS | LUNG |
|---|---|---|
| Price | $4.79 | $1.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $6.50 | $5.38 |
| AVG Volume (30 Days) | ★ 4.0M | 354.0K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $174.68 | $2.48 |
| Revenue Next Year | $53.17 | $18.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.77 | $1.13 |
| 52 Week High | $10.50 | $3.88 |
| Indicator | USAS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 42.78 |
| Support Level | $4.64 | $1.20 |
| Resistance Level | $5.12 | $1.67 |
| Average True Range (ATR) | 0.39 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 17.46 | 17.50 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.